Abstract
Osteoporosis is a condition associated with decreased bone strength and an increased fracture risk. It may be defined based on bone mineral density (BMD) with a T-score at the hip or spine of less than −2.5 standard deviations in young healthy individuals or from an osteoporotic fracture (i.e. a fracture occurring after low-energy trauma or no apparent trauma).
Risk factors predisposing to fractures include: increasing age; female gender; low BMD; a prior fragility fracture; a family history of fragility fractures; low bodyweight; lack of estrogen in women (i.e. post menopause); corticosteroid use; smoking; a number of diseases; deficiency in calcium and vitamin D; an increased risk of falls (i.e. impaired vision); immobilization; and Caucasian race. The more risk factors that are present the higher the risk of fractures over the following 10 years. The need to initiate preventive therapy with anti-osteoporotic treatment increases steeply with the absolute fracture risk.
Indications for referral for dual energy x-ray absorptiometry measurement of BMD include: age >65 years; age <65 years in postmenopausal women with any of the risk factors already mentioned; premature menopause (<45 years); prolonged amenorrhea (>1 year) in younger women; fragility fractures; and diseases or conditions known to lead to osteoporosis.
Antiresorptive therapies include calcium plus vitamin D, bisphosphonates (alendronate, etidronate, risedronate, ibandronate), selective estrogen receptor modulators (raloxifene), hormone replacement therapy, and calcitonin.
Guidelines from several countries on when to initiate antiresorptive therapy state that therapy may be started in patients with a prior fragility fracture (some guidelines state that in this situation no BMD measurements are necessary) or in patients with a T-score of less than −2.5 (some guidelines state that additional risk factors need to be present in this situation). Some guidelines state that antiresorptive therapy may be initiated in patients with a T-score in the osteopenic range (from −1 to −2.5, i.e. not frank osteoporosis) in the presence of other risk factors.
The cost effectiveness of antiresorptive therapy increases with the absolute fracture risk. In some scenarios, treatment with bisphosphonates may be cost effective in a 50-year-old woman with an absolute hip fracture risk of ≥ 1.1% over the next 10 years.
Similar content being viewed by others
References
Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646–50
Alexeeva L, Burkhardt P, Christiansen C, et al. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group [WHO technical report series no. 843]. Geneva, WHO: 1994
Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 1994; 4: 368–81
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785–95
Faulkner KG, Orwoll E. Implications in the use of T-scores for the diagnosis of osteoporosis in men. J Clin Densitom 2002; 5: 87–93
Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int 2005; 16: 134–41
Kelly TJ. Bone mineral density reference database for American men and women [abstract]. J Bone Miner Res 1990; 5Suppl. 2: S249
Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005; 16: 581–9
Dorland’s Illustrated Medical Dictionary. Philadelphia (PA): WB Saunders Co., 1985
Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999; 353: 571–80
Boldsen JL, Jeune B. Distribution of age at menopause in two Danish samples. Hum Biol 1990; 62: 291–300
Flint M. Is there a secular trend in age of menopause? Maturitas 1978; 1: 133–9
Dawson-Hughes B, Gold DT, Rodbard HW, et al. Physician’s guide to prevention and treatment of osteoporosis. Washington (DC): National Osteoporosis Foundation, 2003
Mundy GR, Chen D, Oyajobi BO. Bone remodeling. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of bone metabolism. Washington (DC): ASBMR, 2003: 46–58
Eriksen EF, Vesterby A, Kassem M, et al. Bone remodeling and bone structure. In: Mundy GR, Martin TJ, editors. Physiology and pharmacology of bone. Berlin: Springer Verlag, 1993: 67–109
Vestergaard P, Mosekilde L, Brixen K. Antiresorptive therapy in osteoporosis. Ugeskr Laeger 2005; 167: 883–7
Blake GM, Wahner HW, Fogelman I. The evaluation of osteoporosis: dual energy x-ray absorptiometry and ultrasound in clinical practice. London: Martin Dunitz, 1999
Leib ES, Lewiecki EM, Brinkley N, et al. Official positions of the International Society for Clinical Densitometry. J Clin Densitom 2004; 7: 1–6
Riggs BL, Melton III LJ. Evidence for two distinct syndromes of involutional osteoporosis. Am J Med 1983; 75: 899–901
Vestergaard P, Krogh K, Rejnmark L, et al. Fracture rates and risk factors for fractures in patients with spinal cord injury. Spinal Cord 1998; 36: 790–6
Black DM, Cummings SR, Kerpf DB, et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535–41
Roy DK, O’Neill TW, Finn JD, et al. Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 2003; 14: 19–26
Rea JA, Chen MB, Li J, et al. Morphometric x-ray absorptiometry and morphometric radiography of the spine: a comparison of prevalent vertebral deformity identification. J Bone Miner Res 2000; 15: 564–74
Greenspan SL, von Stetten E, Emond SK, et al. Instant vertebral assessment: a noninvasive dual x-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis. J Clin Densitom 2001; 4: 373–80
Watts NB, Josse RG, Hamdy RC, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2003; 88: 542–9
Vestergaard P, Mosekilde L. Fracture risk associated with smoking: a meta-analysis. J Intern Med 2003; 254: 572–83
Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk: a meta-analysis. Thyroid 2003; 13: 585–93
Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15: 721–39
Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. Bone 2004; 35: 1029–37
Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with systemic and topical corticosteroids. J Intern Med 2005; 257: 374–84
Vestergaard P. Fracture risk secondary to disease [thesis]. Aarhus: Faellestrykkeriet for Sundhedsvidenskab, 2003
Stein E, Shane E. Secondary osteoporosis. Endocrinol Metab Clin North Am 2003; 32: 115–34
van Staa TP, Abenhaim L, Cooper C, et al. Public health impact of adverse bone effects of oral corticosteroids. Br J Clin Pharmacol 2001; 51: 601–7
Prevention and management of osteoporosis. WHO technical report series no. 921. Geneva: WHO, 2003
Wilson JNG, Jungner F. Principles and practice of screening for disease [public health papers no. 34]. Geneva: WHO, 1968
Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 24–35
Cranney A, Guyatt G, Krolicki N, et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2001; 12: 140–51
Cranney A, Tugwell P, Wells G, et al. Meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 496–507
Cranney A, Wells G, Willan A, et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23: 508–16
Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 540–51
Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 524–8
Cranney A, Tugwell P, Adachi J, et al. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 517–23
Cranney A, Guyatt G, Griffith L, et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570–8
Papadimitropoulos E, Wells G, Shea B, et al. Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23: 560–9
Shea B, Wells G, Cranney A, et al. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002; 23: 552–9
Wells G, Tugwell P, Shea B, et al. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23: 529–39
Osteoporosis in the European Community. Action plan (a report of the European Osteoporosis Consultation Panel, IOF-EC-Policy4, Nov 03). Brussels: European Community, 2003
Cheung AM, Feig DS, Kapral M, et al. Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ 2004; 170: 1665–7
Changes in the criteria for reimbursement of bisphosphonates or raloxifene for preventing osteoporosis [abstract]. Ugeskr Laeger 2000; 162: 6512
Fuleihan GE, Baddoura R, Awada H, et al. Practice guidelines on the use of bone mineral density measurements who to test? What measures to use? When to treat? A Consensus report from the Middle East Densitometry Workshop. Leb Med J 2002; 50: 89–104
Raef H, Frayha HH, El-Shaker M, et al. Recommendations for the diagnosis and management of osteoporosis: a local perspective. Ann Saudi Med 2004; 24: 242–52
North American Menopause Society. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause 2002; 9: 84–101
Jorgensen JT, Andersen PB, Rosholm A, et al. Digital x-ray radiogrammetry: a new appendicular bone densitometric method with high precision. Clin Physiol 2000; 20: 330–5
Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15: 1526–36
Vestergaard P, Hermann AP, Gram J, et al. Evaluation of methods for prediction of bone mineral density by clinical and biochemical variables in perimenopausal women. Maturitas 2001; 40: 211–20
Sen SS, Rives VP, Messina OD, et al. A risk assessment tool (OsteoRisk) for identifying Latin American women with osteoporosis. J Gen Intern Med 2005; 20: 245–50
Cadarette SM, Jaglal SB, Murray TM, et al. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA 2001; 286: 57–63
Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001; 12: 519–28
Wallace LS, Ballard JE, Holiday D, et al. Evaluation of decision rules for identifying low bone density in postmenopausal African-American women. J Natl Med Assoc 2004; 96: 290–6
Koh LK, Sedrine WB, Torralba TP, et al. A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporos Int 2001; 12: 699–705
Geusens P, Hochberg MC, van der Voort DJ, et al. Performance of risk indices for identifying low bone density in postmenopausal women. Mayo Clin Proc 2002; 77: 629–37
Clinical practice guidelines for the diagnosis and management of osteoporosis: Scientific Advisory Board, Osteoporosis Society of Canada. CMAJ 1996; 155: 1113–33
Kanis JA, Torgerson D, Cooper C. Comparison of the European and USA practice guidelines for osteoporosis. Trends Endocrinol Metab 2000; 11: 28–32
Kleerekoper M. Treatment of osteoporosis. Clin Obstet Gynecol 2004; 47: 413–23
Compston JE, Papapoulos SE, Blanchard JF. Report on osteoporosis in the European community: current status and recommendations for the future. Osteoporos Int 1998; 8: 531–4
Eastell R, Reid DM, Compston J, et al. A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998; 244: 271–92
Eastell R, Reid DM, Compston J, et al. Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action? QJM 2001; 94: 575–97
Genant HK, Cooper C, Poor G, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 1999; 10: 259–64
Meunier PJ, Delmas PD, Eastell R, et al. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin Ther 1999; 21: 1025–44
Morii H, Genant HK. Statement on the diagnosis and management of osteoporosis from the Consensus Development Conference at the Second International Conference on Osteoporosis, Osaka 1997. J Bone Miner Metab 1998; 16: 206–14
Reginster JY. Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities. J Intern Med 2004; 255: 615–28
Vestergaard P, Rejnmark L, Mosekilde L. Hip fracture prevention: cost-effective strategies. Pharmacoeconomics 2001; 19: 449–68
Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004; 164: 1108–12
Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254–9
Phillips S, Fox N, Jacobs J, et al. The direct medical costs of osteoporosis for American women aged 45 and older, 1986. Bone 1988; 9: 271–9
Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet 1993; 341: 11–3
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33
Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003; 290: 1729–38
The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–12
International Osteoporosis Foundation. Evidence-based guidelines currently available [online]. Available from URL: http://www.osteofound.org/health_professionals/ guidelines/guidelines_list.html [Accessed 2005 May 1]
Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women: Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332: 767–73
Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077–82
Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporosis Int 1999; 8: 468–89
Heaney RP, Zizic TM, Fogelman I, et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002; 13: 501–5
Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 3609–17
McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333–40
Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19: 893–9
Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35: 375–82
Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005 Jul; 16(7): 737–42
Kanis JA, Johansson H, Oden A, et al. A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporos Int 2005 Jul; 16(7): 799–804
Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005 Feb; 16(2): 155–62
Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D, and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637–42
Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994; 308: 1081–2
Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res 2004; 19: 370–8
Trivedi TP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double-blind controlled trial. BMJ 2003; 326: 469–75
Heikinheimo RJ, Inkovaara JA, Harju EJ, et al. Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 1992; 51: 105–10
Lips P, Graafmans WC, Ooms ME, et al. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 1996; 124: 400–6
Meyer HE, Smedshaug GB, Kvaavik E, et al. Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. J Bone Miner Res 2002; 17: 709–15
Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670–6
Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; (2): CD000952
Vestergaard P, Mosekilde L. Economic cost of different intervention regimens to prevent hip fractures. Ugeskr Laeger 1999; 161: 4400–5
Torgerson DJ, Kanis JA. Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. QJM 1995; 88: 135–9
Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium OR vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005; 365: 1621–8
Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005; 330: 1003–9
Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996; 276: 1389–96
Mosekilde L, Beck-Nielsen H, Sorensen OH, et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women: results of the Danish Osteoporosis Prevention Study. Maturitas 2000; 36: 181–93
EMEA. EMEA public statement on recent publications regarding hormone replacement therapy [online]. Available from URL: http://www.emea.eu.int/pdfs/ human/press/pus/3306503en.pdf [Accessed 2005 May 1]
Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–27
Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360: 942–4
Brecht JG, Kruse HP, Mohrke W, et al. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res 2004; 24: 1–10
Brumsen C, Papapoulos SE, Lips P, et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 2002; 17: 1057–64
Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653–61
Ringe JD, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003; 14: 801–7
Liberman UA, Weiss SR, Broil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: the Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437–43
Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 1999; 9: 461–8
Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337: 382–7
Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44: 202–11
Geusens P, Dequeker J, Vanhoof J, et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment: a double-blind, randomised placebo-controlled study. Ann Rheum Dis 1998; 57: 724–7
Jenkins EA, Walker-Bone KE, Wood A, et al. The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. Scand J Rheumatol 1999; 28: 152–6
Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-induced Osteoporosis Treatment Study. J Bone Miner Res 2000; 15: 1006–13
Roux C, Oriente P, Laan R, et al. Randomised trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss: Ciblos Study Group. J Clin Endocrinol Metab 1998; 83: 1128–33
Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292–9
Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003; 18: 919–24
Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67: 277–85
Amin S, Lavalley MP, Simms RW, et al. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002; 17: 1512–26
Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003; 349: 457–63
Jönsson L, Borgström F, Zethraeus N. Omkostningseffektivitet ved alendronatbe-handling af osteoporose i Danmark. Ugeskr Laeger 2003; 165: 4112–6
Chesnut III CH, Silverman S, Andriano KA, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. PROOF Study Group. Am J Med 2000; 109: 267–76
Cranney A, Welch V, Adachi JD, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; (2): CD001983
Vestergaard P, Hermann AP, Gram J, et al. Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. Maturitas 1997; 28: 137–45
Christensen PM, Brixen K, Gyrd-Hansen D, et al. Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 2005; 96: 387–96
Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 2005; 17: 462–6
Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003; 5: 859–62
Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167: S1–34
Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 2003; 163: 2619–24
Acknowledgments
No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vestergaard, P. Antiresorptive Therapy for the Prevention of Postmenopausal Osteoporosis. Mol Diag Ther 4, 263–277 (2005). https://doi.org/10.2165/00024677-200504050-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00024677-200504050-00001